CureVac N.V. (ETR:5CV)
Germany
· Delayed Price · Currency is EUR | Market Cap | 1.07B |
| Revenue (ttm) | 523.70M |
| Net Income (ttm) | 180.66M |
| Shares Out | n/a |
| EPS (ttm) | 0.80 |
| PE Ratio | 5.94 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 57,294 |
| Average Volume | 250,194 |
| Open | 4.700 |
| Previous Close | 4.750 |
| Day's Range | 4.666 - 4.722 |
| 52-Week Range | 2.000 - 4.900 |
| Beta | 2.49 |
| RSI | 69.82 |
| Earnings Date | Aug 15, 2025 |
About CureVac
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company’s portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRNAs to stimulate the production of therapeutic proteins utilizing its technology and instructs human cells to produce or secrete specific proteins in the nucleus, cytoplasm, cellular organelles, and cell membrane. In ad... [Read more]
Financial Performance
Financial StatementsNews
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVAC, KNW, SOAR, HLGN on Behalf of Shareholders
NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breac...
This Sherwin-Williams Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag...
BioNTech's Acquisition Of CureVac Brings Complementary Method To Target Cancer
The BioNTech SE acquisition of CureVac N.V. brings together complementary technologies, as both are developing mRNA candidates. Click for my look at BNTX and CVAC.
Stocks making the biggest midday moves: Oracle, Boeing, CureVac, Datadog and more
Here are the stocks making headlines in Thursday's trading.
Top Stock Movers Now: Oracle, Boeing, CureVac, and More
U.S. equities were mixed and little changed at midday as a second inflation report this week came in lower than anticipated.
BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal
BioNTech SE BNTX on Thursday agreed to acquire CureVac N.V. CVAC in an all-stock transaction.
BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal
BioNTech SE (NASDAQ: BNTX) on Thursday agreed to acquire CureVac N.V. (NASDAQ: CVAC) in an all-stock transaction . According to the agreement, shareholders can exchange CureVac shares for around $5....
CureVac, TELUS International, Oracle And Other Big Stocks Moving Higher On Thursday
U.S. stocks were higher, with the Dow Jones index gaining around 0.1% on Thursday. Shares of CureVac N.V. (NASDAQ: CVAC) rose sharply during Thursday's session after BioNTech announced it will acquir...
Stocks to Watch Thursday: Boeing, Oracle, Oklo, CureVac
COVID-19 Vaccine Maker BioNTech Buys CureVac as It Aims for Cancer Treatments
CureVac shares skyrocketed 35% Thursday when the biotech firm agreed to be bought by COVID-19 vaccine maker BioNTech in an all-stock deal valued at about $1.25 billion.
CVAC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of CureVac N.V. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of CureVac N.V. (NASDAQ: CVAC) to BioNTech SE is fair to CureVac shareholders. Under the terms of the proposed transact...
CVAC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of CureVac N.V. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of CureVac N.V. (NASDAQ: CVAC) to BioNTech SE is fair to CureVac shareholders. Under the ter...
BioNTech to Acquire CureVac in Stock Deal Valued Around $1.25 Billion
BioNTech to Buy CureVac in $1.25 Billion Deal. Both Stocks Are Rising.
BioNTech to acquire CureVac in $1.25 billion all-stock deal
German biotech firm BioNTech said on Thursday it agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares to boost its work on new mRNA-based cancer treatments.
BioNTech to buy German rival CureVac for $1.25B in all-stock deal
CureVac BV reports Q1 results
CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates
U.S. FDA clears lung cancer IND for CVHNLC, a proprietary off-the-shelf candidate targeting squamous non-small cell lung cancer (sqNCLC), with clinical study expected to begin H2 2025; Clinical Trial ...
CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates
U.S. FDA clears lung cancer IND for CVHNLC, a proprietary off-the-shelf candidate targeting squamous non-small cell lung cancer (sqNCLC), with clinical study expected to begin H2 2025; Clinical Trial ...
CureVac Unveils Q1 2025 Financial Results & Business Updates!
CureVac is forging ahead with innovative clinical trials and strategic patent victories, positioning itself for a promising future in the biotech industry. Jetzt den vollständigen Artikel lesen
EQS-News: CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates
Issuer: CureVac / Key word(s): Quarter Results CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates 20.05.2025 / 13:00 CET/CEST The issuer is solely responsi...
CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE
European Patent Office largely dismisses opposition filed by BioNTech SE, Pfizer Inc., and others in December 2023 challenging validity of EP 4 023 755 B1 and maintains the patent subject to amendment...
CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE
European Patent Office largely dismisses opposition filed by BioNTech SE, Pfizer Inc., and others in December 2023 challenging validity of EP 4 023 755 B1 and maintains the patent subject to amendment...
BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expansion
BioNTech SE (NASDAQ: BNTX) on Monday reported a first-quarter per-share loss of $1.82 (1.73 euros), up from 1.31 euros reported a year ago compared to beating the consensus of $2.02 . The COVID-19 va...